AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: D.Right who wrote (986)	11/30/1997 9:59:00 PM
From: David Bogdanoff	Read Replies (1) of 2173

DR: The decreased use of insulin in the pramlintide group vs. increased use in the control group is called a confounding factor in statistical terminology. There are statistical techniques for dealing with confounding factors; in some cases it is possible to adjust for the effects of the differential dosage and determine the effects of the treatment after adjusting for effects of the confounding factor. Using such techniques can obviate the need for more controlled experimentation. Question is, why didn't the Amylin clinical studies researchers do this? A couple of answers come to mind: 1) they simply didn't know of this possibility . 2) it was done, or considered, butthe data collected was not of high enough quality to give reliable results and so further testing was opted for. The second scenario would explain why they have such confidence of an ultimate positive outcome. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next